|
Physiomics plc works with partners from both small and large
pharmaceutical and biotechnology companies. These include Cyclacel Pharmaceutical, Eli Lilly
and ValiRx.
Our technology has conferred many benefits to our partners:
|
Our apoptosis model technology has supported both “no-go” and “go” decisions
for therapeutic targets. George Morris, Chief Development Officer of ValiRx,
said: "Physiomics service and technology is absolutely superb, we (ValiRx)
have just had some work carried out and it has saved us very significant amounts
of development money and time. This is the first time the research has been
done this way....."
|
|
|
We are developing our technology with both industrial and academic partners across the European Union:
|
|
As part of the TEMPO project we are developing combined
pharmacokinetic-pharmacodynamic models of cancer processes in order to determine optimal
chronotherapeutic scheduling for cell cycle inhibitors. The aim is that this will support a
clinical trial in the future.
|
|
|
We are also working with other industrial partners to develop and enhance our technological capability:
|
|
|
If you are interested in knowing more about Physiomics and
how we might deliver benefit to your research effort, please contact us.
Back to the top
|
